Drug Search Results
More Filters [+]

Aviscumine

Alternative Names: aviscumine, cy-503, cy 503, cy503
Latest Update: 2013-07-10
Latest Update Note: Clinical Trial Update

Product Description

Aviscumine, a recombinant lectin I, has been identified as an immunomodulatory agent within a new class of ribotoxic stress-inducing anticancer substances that have demonstrated efficacy in phase I/II trials. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5666656/)

Mechanisms of Action: 28S Ribosomal Subunit Deactivator

Novel Mechanism: Yes

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cytavis Biopharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Aviscumine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Colorectal Cancer|Melanoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CY503C2

P2

Terminated

Colorectal Cancer

2012-08-01

CY-503 Phase II Malignant Melanoma

P2

Completed

Melanoma

2011-12-31

2008-005536-32

P2

Terminated

Colorectal Cancer

2011-06-28

CY503C1

P2

Completed

Melanoma

2009-08-01

Recent News Events

Date

Type

Title